Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Other Non Operating Income (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Other Non Operating Income for 10 consecutive years, with $2000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non Operating Income rose 107.69% year-over-year to $2000.0, compared with a TTM value of $106000.0 through Sep 2025, up 402.86%, and an annual FY2024 reading of $60000.0, up 528.57% over the prior year.
  • Other Non Operating Income was $2000.0 for Q3 2025 at Spero Therapeutics, down from $4000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $966000.0 in Q4 2022 and bottomed at -$317000.0 in Q3 2021.
  • Average Other Non Operating Income over 5 years is $30263.2, with a median of -$6000.0 recorded in 2023.
  • The sharpest move saw Other Non Operating Income crashed 676.36% in 2021, then surged 2375.0% in 2024.
  • Year by year, Other Non Operating Income stood at -$78000.0 in 2021, then skyrocketed by 1338.46% to $966000.0 in 2022, then tumbled by 99.59% to $4000.0 in 2023, then soared by 2375.0% to $99000.0 in 2024, then tumbled by 97.98% to $2000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for SPRO at $2000.0 in Q3 2025, $4000.0 in Q2 2025, and $1000.0 in Q1 2025.